(Q44672181)

5 December 2017

Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial (English)

1 reference

5 December 2017

0 references

1 reference

1 reference

1

1 reference

5 December 2017

8

1 reference

5 December 2017

Tero Hallikainen

2

1 reference

5 December 2017

Olli-Pekka Ryynänen

3

1 reference

5 December 2017

Eila Repo-Tiihonen

4

1 reference

5 December 2017

Irma Kotilainen

5

1 reference

5 December 2017

Markku Eronen

6

1 reference

5 December 2017

Päivi Toivonen

7

1 reference

5 December 2017

Anu Putkonen

9

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

5 December 2017

Biological Psychiatry

1 reference

5 December 2017

54

1 reference

5 December 2017

1241-1248

1 reference

5 December 2017

11

1 reference

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

5 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Lamotrigine in the treatment of bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

A Coefficient of Agreement for Nominal Scales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Flunarizine inhibits both calcium-dependent and -independent release of glutamate from synaptosomes and cultured neurones.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Clozapine plus lamotrigine in treatment-resistant schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Placebo-controlled trial of glycine added to clozapine in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

The Drug-Placebo Response Curve: A New Method for Assessing Drug Effects in Clinical Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

D-cycloserine added to clozapine for patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Lamotrigine may limit pathological excitation in the hippocampus by modulating a transient potassium outward current.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Lamotrigine update and its use in mood disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Amelioration of negative symptoms in schizophrenia by glycine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Elevated clozapine plasma level with lamotrigine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Neurochemical and Behavioral Aspects of Lamotrigine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

D-serine added to antipsychotics for the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2803%2900524-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(03)00524-9

1 reference

5 December 2017

1 reference